EPO-ProgMS
Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis
What was tested
Treatment tested
- Methylprednisolone hemisuccinate
What it measured
Main measures
The primary end point is the change from baseline to 24 weeks in a composite score of maximum gait distance, 9-hole peg test and TRAIL making B test, comparing the placebo treated group with the NeoRecomorn group.
Disability progressionWalking and mobility
Loading reviews and guidelines…
Related trials
- GAVOTTE
Phase 3 · Running, not recruiting
Missed its main goal
- EFFRITE
Phase 2 · Completed
No result found
- SCALA
Phase 1 · Completed
Result in a paper, not read yet
- EFFRITE
Phase 2 · Completed
Missed its main goal
- COMTiMS
Phase 2 · Completed
Result in a paper, not read yet
- EPO-ProgMS
Phase 2 · Status unknown
No result found
History
- In scope changed from true to false
Started
May 2009
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error